Brookline Capital Management Equities Analysts Lift Earnings Estimates for SQZ Biotechnologies (NYSE:SQZ)

SQZ Biotechnologies (NYSE:SQZ – Get Rating) – Equities research analysts at Brookline Capital Management increased their FY2026 EPS estimates for shares of SQZ Biotechnologies in a report released on Wednesday, May 10th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings of $17.70 per share for the year, up from […]

Related Keywords

,Citadel Advisors ,Millennium Management ,Jpmorgan Chase Co ,Charles Schwab Investment Management Inc ,Biotechnologies Company ,Renaissance Technologies ,Biotechnologies Company Profile ,Get Rating ,Brookline Capital Management ,Capital Management ,Schwab Investment Management ,Presenting Cells ,Sqz Biotechnologies ,Nyse Sqz ,Sqz ,Medical ,Earnings Estimates ,